Answer 5 questions to find out.
Yes, for people who qualify, from July 1, 2026 through December 31, 2027. The Medicare GLP-1 Bridge covers Wegovy and the Zepbound pen for $50 a month. Your doctor has to get approval first. It does not cover Zepbound vials, Ozempic or Mounjaro for weight loss. Source: Medicare.gov.
Adults with a body mass index (BMI) of 35 or more. Or a BMI of 30 or more with heart failure, high blood pressure that is hard to control, or kidney disease stage 3 or worse. Or a BMI of 27 or more with prediabetes, a past heart attack or stroke, or poor blood flow in the legs with pain. People with type 2 diabetes, sleep apnea or fatty liver disease get these drugs through their Part D plan instead. Source: Medicare.gov.
For type 2 diabetes, almost every Medicare drug plan lists them. In Medicare's September 2026 drug-list file, Ozempic is on 5,003 of 5,052 plans and Mounjaro is on 4,899. Almost every plan needs your doctor to get approval first. Medicare drug plans cannot cover them for weight loss. Source: CMS drug-list files.
It depends on your state. North Carolina covers Wegovy for weight loss with approval. Virginia and Michigan cover it only with strict BMI rules. California and Pennsylvania stopped covering weight-loss use on January 1, 2026. Many states still cover these drugs for diabetes, heart risk or sleep apnea. The check above links to each state's own list.
From the drug makers' own pharmacies: the Wegovy shot is $349 a month, or $399 for the highest dose, and the Wegovy pill starts at $149. The Zepbound pen is $299 to $449 a month, depending on the dose. Ozempic is $349 a month, or $499 for the highest dose. Sources: NovoCare, Lilly.
No. The check asks for your drug, why you take it, and what kind of insurance you have. For Medicare drug plans it can use the plan number on your card, but that is optional. It never asks for your name, birth date or member number.
We keep your email, your answers and any file you send, so we can tell you if your coverage changes. To delete them, email [email protected].